Extended Data Fig. 4: P2G3 LS confers potent in vivo efficacy in the hamster challenge model for SARS-CoV-2 infection. | Nature Microbiology

Extended Data Fig. 4: P2G3 LS confers potent in vivo efficacy in the hamster challenge model for SARS-CoV-2 infection.

From: Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

Extended Data Fig. 4: P2G3 LS confers potent in vivo efficacy in the hamster challenge model for SARS-CoV-2 infection.The alternative text for this image may have been generated using AI.

a) Overview of study design for the SARS-CoV-2 hamster challenge model. Animals were administered intraperitoneally 5.0, 1.0 or 0.5 mgkg−1 of P2G3, 5 mg/kg of REGN10933 positive control or 5 mg/kg of an IgG1 isotype control and challenged two days later (Day 0) with an intranasal inoculation of the original 2019-nCoV SARS-CoV-2 virus (2.4 ×106 TCID50). b) Median levels of infectious virus and c) viral RNA copies/mg lung tissue in each of the study arms are shown on day 4 post-inoculation with SARS-CoV-2 virus. Treatment arms for IgG control, REGN10933 5 mg/kg, P2G3 5 mg/kg, P2G3 1.0 mg/kg and P2G3 0.5 mg/kg consist of n = 6, 5, 4, 5, and 6 hamsters, respectively. Non-parametric Mann-Whitney U- two-sided tests were used to evaluate the statistical difference between the treatment conditions with p = 0.0043, 0.0095, 0.0043 and 0.0022 (from left to right, **) in b and p = 0.0043, 0.0095, 0.0043 and 0.0022 (from left to right, **) in c.

Source data

Back to article page